Adenosine triphosphate-competitive mTOR inhibitors: A New class of immunosuppressive agents that inhibit allograft rejection

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 2173-2180

  Rosborough, B R ^a   Raich Regue D ^a   Liu, Q ^a   Venkataramanan, R ^b   Turnquist, H R ^a   Thomson, A W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Basic (laboratory) research; biology; immune modulation; immunosuppressant; immunosuppression; mechanistic target of rapamycin (mTOR); science; T cell

Indexed keywords

ADENOSINE TRIPHOSPHATE; AZD 8055; GAMMA INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; IMMUNOSUPPRESSIVE AGENT; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; PRIMER DNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THERAPY EFFECT; ANIMAL; BINDING COMPETITION; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOLOGY; DRUG EFFECTS; GRAFT REJECTION; METABOLISM; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BASE SEQUENCE; BINDING, COMPETITIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DNA PRIMERS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; POLYMERASE CHAIN REACTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84906250192     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12799     Document Type: Article

References (24)

1. Thomson AW, Turnquist HR, Raimondi G., Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9: 324-337.
2. Powell JD, Pollizzi KN, Heikamp EB, Horton MR., Regulation of immune responses by mTOR. Annu Rev Immunol 2012; 30: 39-68.
3. Webster AC, Lee VW, Chapman JR, Craig JC., Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
4. Guertin DA, Sabatini DM., The pharmacology of mTOR inhibition. Sci Signal 2009; 2: pe24.
5. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
6. Sarbassov DD, Ali SM, Kim D-H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14: 1296-1302.
7. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128.
8. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159-168.
9. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e1000038.
10. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70: 288-298.
11. Rosborough BR, Raich-Regue D, Matta BM, et al. Murine dendritic cell rapamycin-resistant and rictor-independent mTOR controls IL-10, B7-H1 and regulatory T-cell induction. Blood 2013; 121: 3619-3630.
12. Brown J, Wang H, Suttles J, Graves DT, Martin M., Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem 2011; 286: 44295-44305.
13. Lee K, Gudapati P, Dragovic S, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010; 32: 743-753.
14. Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011; 12: 295-303.
15. + T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS. Blood 2010; 115: 4758-4769.
16. Matta BM, Raimondi G, Rosborough BR, Sumpter TL, Thomson AW., IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells. J Immunol 2012; 188: 5227-5237.
17. + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187: 4598-4610.
18. Holt DW, Lee T, Jones K, Johnston A., Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000; 46: 1179-1183.
19. -/- mice by delaying carcinogenesis. Aging (Albany NY) 2012; 4: 715-722.
20. Naing A, Aghajanian C, Raymond E, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer 2012; 107: 1093-1099.
21. Asahina H, Nokihara H, Yamamoto N, et al. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors: A dose-finding phase I study. Invest New Drugs 2013; 31: 677-684.
22. Pike KG, Malagu K, Hummersone MG, et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett 2013; 23: 1212-1216.
23. Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y., Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun 2014; 443: 406-412.
24. Zhang L, You J, Sidhu J, et al. Abrogation of chronic rejection in rat model system involves modulation of the mTORC1 and mTORC2 pathways. Transplantation 2013; 96: 782-790.